Brief: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
08/07/2025 12:39
July 8 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES INITIAL PATIENTS SUCCESSFULLY TREATED IN RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQ™ IN LEPTOMENINGEAL METASTASES PLUS THERAPEUTICS INC - COMPANY TO REQUEST END OF PHASE 1 MEETING WITH FDA Source text: ID:nGNX8WBtyN Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer